Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass.
body composition
chemo-toxicity
head and neck cancer
muscular mass
nutritional status
taxotere-platine-fluorouracil
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
17
11
2021
received:
07
06
2021
accepted:
03
12
2021
pubmed:
18
12
2021
medline:
17
3
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
To assess the impact of nutritional status on tolerance to induction chemotherapy by docetaxel, cisplatin and 5-fluorouracil (ICT) in head and neck cancer (HNC). Ninety-two HNC patients were included. Toxicity was assessed according to common terminology criteria for adverse events. Nutritional status was assessed by body mass index (BMI), serum albumin, nutritional risk index (NRI), and CT scan (skeletal muscle mass index [SMI] at the first lumbar vertebral level). Before treatment, average BMI was 22.7 ± 4.6 kg/m Low skeletal muscle mass is a predictive factor of toxicity to ICT in HNC.
Sections du résumé
BACKGROUND
To assess the impact of nutritional status on tolerance to induction chemotherapy by docetaxel, cisplatin and 5-fluorouracil (ICT) in head and neck cancer (HNC).
METHODS
Ninety-two HNC patients were included. Toxicity was assessed according to common terminology criteria for adverse events. Nutritional status was assessed by body mass index (BMI), serum albumin, nutritional risk index (NRI), and CT scan (skeletal muscle mass index [SMI] at the first lumbar vertebral level).
RESULTS
Before treatment, average BMI was 22.7 ± 4.6 kg/m
CONCLUSION
Low skeletal muscle mass is a predictive factor of toxicity to ICT in HNC.
Substances chimiques
Docetaxel
15H5577CQD
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-690Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 - Tumeurs solides: Étude à partir des registres des cancers du réseau Francim. https://www.santepubliquefrance.fr/maladies-et-traumatismes/cancers/cancer-du-sein/documents/rapport-synthese/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-volume-1-tumeurs-solides-etud. Accessed February 26, 2021.
Saroul N, Pastourel R, Mulliez A, et al. Which assessment method of malnutrition in head and neck cancer? Otolaryngol Head Neck Surg. 2018;158:1065-1071. doi:10.1177/0194599818755995
Pignon J-P, Le Maître A, Bourhis J, MACH-NC Collaborative Group. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112-S114. doi:10.1016/j.ijrobp.2007.04.088
Pignon J-P, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14. doi:10.1016/j.radonc.2009.04.014
Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949-955.
Blanchard P, Bourhis J, Lacas B, et al. Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: principles, results and perspectives. Cancer Radiother. 2015;19:198-204; quiz 228-229, 233. 10.1016/j.canrad.2014.12.009
Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol. 2010;21:1515-1522. doi:10.1093/annonc/mdp573
Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216-225. doi:10.1093/annonc/mdt461
Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2018;36:3077-3083. doi:10.1200/JCO.2017.76.2591
Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735-2743. doi:10.1200/JCO.2013.54.6309
Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257-264. doi:10.1016/S1470-2045(13)70011-1
Pointreau Y, Schick U, Huguet F. Role and interest of induction chemotherapy for head and neck cancers. Cancer Radiother. 2017;21:505-509. doi:10.1016/j.canrad.2017.07.034
Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med. 1991;325:525-532. doi:10.1056/NEJM199108223250801
Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of cancer phase III trial. EORTC head and neck cancer cooperative group. J Natl Cancer Inst. 1996;88:890-899. doi:10.1093/jnci/88.13.890
Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498-506. doi:10.1093/jnci/djp007
Balermpas P, Bauer C, Fraunholz I, et al. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol. 2014;190:256-262. doi:10.1007/s00066-013-0509-9
Takácsi-Nagy Z, Hitre E, Remenár É, et al. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: results of a randomized phase II study. Strahlenther Onkol. 2015;191:635-641. doi:10.1007/s00066-015-0829-z
Garden AS. Is there still a role for induction chemotherapy for head and neck cancer? J Clin Oncol. 2005;23:1059-1060. doi:10.1200/JCO.2005.09.925
Garden AS. The never-ending story: finding a role for neoadjuvant chemotherapy in the management of head and neck cancer. J Clin Oncol. 2014;32:2685-2686. doi:10.1200/JCO.2014.56.7685
Bernadach M, Lapeyre M, Dillies AF, et al. Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: the importance of nutritional status. Cancer Radiother. 2019;23:273-280. doi:10.1016/j.canrad.2018.08.003
Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491-497. doi:10.1016/s0149-2918(05)80001-3
Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. Clin Nutr. 2019;38:1-9. doi:10.1016/j.clnu.2018.08.002
Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91:1133S-1137S. doi:10.3945/ajcn.2010.28608C
Surov A, Wienke A. Sarcopenia predicts overall survival in patients with malignant hematological diseases: a meta-analysis. Clin Nutr. 2021;40:1155-1160. doi:10.1016/j.clnu.2020.07.023
Bundred J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford). 2019;21:1603-1612. doi:10.1016/j.hpb.2019.05.018
Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: systematic review and meta-analysis. Int J Surg. 2018;59:19-26. doi:10.1016/j.ijsu.2018.09.014
Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18:3579-3585. doi:10.1245/s10434-011-1976-9
Ubachs J, Ziemons J, Minis-Rutten IJG, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:1165-1174. doi:10.1002/jcsm.12468
Wong A, Zhu D, Kraus D, Tham T. Radiologically defined sarcopenia affects survival in head and neck cancer: a meta-analysis. Laryngoscope. 2021;131:333-341. doi:10.1002/lary.28616
Hua X, Liu S, Liao J-F, et al. When the loss costs too much: a systematic review and meta-analysis of sarcopenia in head and neck cancer. Front Oncol. 2019;9:1561. doi:10.3389/fonc.2019.01561
Surov A, Wienke A. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis. Ther Adv Med Oncol. 2021;13:17588359211008844. doi:10.1177/17588359211008844
van Rijn-Dekker MI, van den Bosch L, van den Hoek JGM, et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2020;147:103-110. doi:10.1016/j.radonc.2020.03.014
Diagnostic de la dénutrition de l'enfant et de l'adulte. In: Haute Autorité de Santé. https://www.has-sante.fr/jcms/p_3118872/fr/diagnostic-de-la-denutrition-de-l-enfant-et-de-l-adulte. Accessed May 21, 2021.
Buzby GP, Knox LS, Crosby LO, et al. Study protocol: a randomized clinical trial of total parenteral nutrition in malnourished surgical patients. Am J Clin Nutr. 1988;47:366-381. doi:10.1093/ajcn/47.2.366
Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920-2926. doi:10.1158/1078-0432.CCR-08-2242
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495. doi:10.1016/S1470-2045(10)70218-7
Kim EY, Kim YS, Park I, et al. Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Support Care Cancer. 2016;24:4721-4726. doi:10.1007/s00520-016-3321-0
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
Joglekar S, Nau PN, Mezhir JJ. The impact of sarcopenia on survival and complications in surgical oncology: a review of the current literature. J Surg Oncol. 2015;112:503-509. doi:10.1002/jso.24025
Achim V, Bash J, Mowery A, et al. Prognostic indication of sarcopenia for wound complication after total laryngectomy. JAMA Otolaryngol Head Neck Surg. 2017;143:1159-1165. doi:10.1001/jamaoto.2017.0547
Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594-1598. doi:10.1093/annonc/mdp605
Tan BHL, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333-338. doi:10.1016/j.ejso.2014.11.040
Huiskamp LFJ, Chargi N, Devriese LA, May AM, Huitema ADR, De Bree R. The predictive value of low skeletal muscle mass assessed on cross-sectional imaging for anti-cancer drug toxicity: a systematic review and meta-analysis. J Clin Med. 2020;9:9113780. doi:10.3390/jcm9113780
Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117-124. doi:10.1016/j.radonc.2019.04.023
Sealy MJ, Dechaphunkul T, van der Schans CP, et al. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin Nutr. 2020;39:501-509. doi:10.1016/j.clnu.2019.02.029
Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012
Cho Y, Kim JW, Keum KC, Lee CG, Jeung HC, Lee IJ. Prognostic significance of sarcopenia with inflammation in patients with head and neck cancer who underwent definitive Chemoradiotherapy. Front Oncol. 2018;8:457. doi:10.3389/fonc.2018.00457
Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006. doi:10.1139/H08-075
McClelland S, Andrews JZ, Chaudhry H, et al. Prophylactic versus reactive gastrostomy tube placement in advanced head and neck cancer treated with definitive chemoradiotherapy: a systematic review. Oral Oncol. 2018;87:77-81. doi:10.1016/j.oraloncology.2018.10.028
Jung AR, Roh J-L, Kim JS, et al. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. Eur J Cancer. 2019;116:98-106. doi:10.1016/j.ejca.2019.05.006
Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol. 2016;62:28-33. doi:10.1016/j.oraloncology.2016.09.006
Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97:2333-2338. doi:10.1152/japplphysiol.00744.2004
Deutz NEP, Safar A, Schutzler S, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011;30:759-768. doi:10.1016/j.clnu.2011.05.008
Engelen MPKJ, van der Meij BS, Deutz NEP. Protein anabolic resistance in cancer: does it really exist? Curr Opin Clin Nutr Metab Care. 2016;19:39-47. doi:10.1097/MCO.0000000000000236
Boirie Y, Guillet C. Fast digestive proteins and sarcopenia of aging. Curr Opin Clin Nutr Metab Care. 2018;21:37-41. doi:10.1097/MCO.0000000000000427
Chanet A, Verlaan S, Salles J, et al. Supplementing breakfast with a vitamin D and leucine-enriched whey protein medical nutrition drink enhances postprandial muscle protein synthesis and muscle mass in healthy older men. J Nutr. 2017;147:2262-2271. doi:10.3945/jn.117.252510
Gryson C, Ratel S, Rance M, et al. Four-month course of soluble milk proteins interacts with exercise to improve muscle strength and delay fatigue in elderly participants. J Am Med Dir Assoc. 2014;15:958.e1-958.e9. doi:10.1016/j.jamda.2014.09.011